- Home
- RARE vs CNK Comparison
RARE vs CNK Comparison
Compare RARE & CNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- CNK
- Stock Information
- Founded
- RARE 2010
- CNK 1984
- Country
- RARE United States
- CNK United States
- Employees
- RARE N/A
- CNK N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- CNK Movies/Entertainment
- Sector
- RARE Health Care
- CNK Consumer Discretionary
- Exchange
- RARE Nasdaq
- CNK Nasdaq
- Market Cap
- RARE 3.6B
- CNK 3.2B
- IPO Year
- RARE 2014
- CNK 2007
- Fundamental
- Price
- RARE $33.84
- CNK $24.55
- Analyst Decision
- RARE Strong Buy
- CNK Buy
- Analyst Count
- RARE 15
- CNK 11
- Target Price
- RARE $95.93
- CNK $31.45
- AVG Volume (30 Days)
- RARE 748.6K
- CNK 4.4M
- Earning Date
- RARE 05-01-2025
- CNK 05-01-2025
- Dividend Yield
- RARE N/A
- CNK 0.33%
- EPS Growth
- RARE N/A
- CNK 54.03
- EPS
- RARE N/A
- CNK 2.06
- Revenue
- RARE $560,230,000.00
- CNK $3,049,500,000.00
- Revenue This Year
- RARE $19.15
- CNK $10.02
- Revenue Next Year
- RARE $32.11
- CNK $7.03
- P/E Ratio
- RARE N/A
- CNK $11.91
- Revenue Growth
- RARE 29.01
- CNK N/A
- 52 Week Low
- RARE $33.69
- CNK $16.32
- 52 Week High
- RARE $60.37
- CNK $36.28
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- CNK 38.87
- Support Level
- RARE $36.71
- CNK $24.02
- Resistance Level
- RARE $39.21
- CNK $26.29
- Average True Range (ATR)
- RARE 1.34
- CNK 0.80
- MACD
- RARE -0.32
- CNK 0.14
- Stochastic Oscillator
- RARE 2.19
- CNK 31.72
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.